Skip to main content

Table 1 Comparison of clinical and laboratory features between LEP hypermethylated and non-hypermethylated AML patients

From: Identification and validation of obesity-related gene LEP methylation as a prognostic indicator in patients with acute myeloid leukemia

Patient’s features Non-hypermethylated (n = 68) Hypermethylated (n = 104) P value
Sex, male/female 35/33 69/35 0.057
Median age, years (range) 55.5 (18–85) 55 (18–86) 0.872
Median WBC, × 109/L (range) 12.5 (0.9–528.0) 18.4 (0.3–232.1) 0.626
Median hemoglobin, g/L (range) 76 (32–147) 79 (32–144) 0.951
Median platelets, × 109/L (range) 50 (6–447) 38.3 (3–415) 0.046
Median BM blasts, % (range) 45 (5.5–97.5) 56.5 (1–99) 0.064
FAB classifications    0.044
 M0 0 2  
 M1 5 6  
 M2 21 45  
 M3 19 10  
 M4 15 20  
 M5 7 14  
 M6 1 5  
 No data 0 2  
Karyotypes    0.042
 Normal 24 52  
 t(8;21) 4 8  
 inv(16) 0 2  
 t(15;17) 19 8  
 +8 2 3  
 -5/5q- 1 0  
 -7/7q- 0 1  
 t(9;22) 1 1  
 11q23 0 2  
 Complex 7 10  
 Others 7 9  
 No data 3 8  
Gene mutations    
 CEBPA (±) 4/53 12/69 0.187
 NPM1 (±) 5/52 10/71 0.587
 FLT3-ITD (±) 4/53 8/73 0.761
 C-KIT (±) 5/52 3/78 0.274
 N/K-RAS (±) 3/54 12/69 0.098
 IDH1/2 (±) 3/54 2/79 0.404
 DNMT3A (±) 2/55 6/75 0.470
 U2AF1 (±) 0/57 3/78 0.267
 SRSF2 (±) 3/54 1/80 0.306
 SETBP1 (±) 0/57 2/79 0.512
CR, total AML (±) 33/26 29/56 0.011
CR, non-M3 AML (±) 20/22 23/56 0.049
CR, CN-AML (±) 11/9 14/29 0.105
  1. Patients’ blasts less than 20% with t(15;17) cytogenetic aberrations
  2. WBC white blood cells, BM bone marrow, FAB French-American-British classification, CR complete remission
\